KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Deferred Taxes: 2022-2024

Historic Deferred Taxes for Nektar Therapeutics (NKTR) over the last 2 years, with Sep 2024 value amounting to -$31,000.

  • Nektar Therapeutics' Deferred Taxes fell 106.67% to -$31,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $1.7 million, marking a year-over-year increase of 99.30%. This contributed to the annual value of -$140,000 for FY2023, which is 105.17% down from last year.
  • As of Q3 2024, Nektar Therapeutics' Deferred Taxes stood at -$31,000, which was down 154.39% from $57,000 recorded in Q2 2024.
  • In the past 5 years, Nektar Therapeutics' Deferred Taxes registered a high of $2.7 million during Q4 2022, and its lowest value of -$1.8 million during Q1 2023.
  • Moreover, its 3-year median value for Deferred Taxes was -$21,000 (2023), whereas its average is $319,500.
  • Within the past 5 years, the most significant YoY rise in Nektar Therapeutics' Deferred Taxes was 311.11% (2024), while the steepest drop was 106.67% (2024).
  • Quarterly analysis of 3 years shows Nektar Therapeutics' Deferred Taxes stood at $2.7 million in 2022, then plummeted by 36.71% to $1.7 million in 2023, then tumbled by 106.67% to -$31,000 in 2024.
  • Its Deferred Taxes was -$31,000 in Q3 2024, compared to $57,000 in Q2 2024 and -$38,000 in Q1 2024.